SDGR - Why Shares of Allogene Therapeutics Beam Therapeutics Intellia Therapeutics and Schrödinger Are Volatile This Week
After the Food and Drug Administration paused Allogene Therapeutics ' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. It has rebounded 31% this week through Thursday, according to data from S&P Global Market Intelligence . That still leaves it down 30% since the beginning of the month.
The FDA's intervention appeared to spur trading by ARK Invest in Beam Therapeutics (NASDAQ: BEAM) , Intellia Therapeutics (NASDAQ: NTLA) , and Schrödinger (NASDAQ: SDGR) . Beam, Intellia, and Schrödinger were up roughly 13%, 9%, and 10%, respectively, this week through Thursday, also according to data from S&P Global Market Intelligence .
Image source: Getty Images.
For further details see:
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week